Evidence map›Paper›PMID 34485274›Full record

ArticleFrontiers in cell and developmental biology2021

CRISPR/Cas9-Mediated

Sanchuan Luo, Zhongxiang Li, Xin Dai, Rui Zhang, Zhibing Liang, Wenzhou Li, Ming Zeng, Jinfeng Su, Jun Wang, Xia Liang and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Isolated A1-domainResearch and practice in thrombosis and haemostasis · 2026
    Article
  2. Exploring gene editing as a potential therapeutic strategy for hemophilia.Frontiers in bioengineering and biotechnology · 2026
    Review
  3. Advancements in CRISPR-basedFrontiers in genome editing · 2026
    Review
  4. CRISPR and gene editing technologies for bleeding disorders.Therapeutic advances in hematology · 2025
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Correction ofFrontiers in genetics · 2023
    Article
  10. Application of Gene Therapy in Hemophilia.Current medical science · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Sanchuan LuoMedical Research Institute, Shenzhen Baoan Women's and Children's Hospital, Jinan University, Shenzhen, China.
Zhongxiang LiMedical Research Institute, Shenzhen Baoan Women's and Children's Hospital, Jinan University, Shenzhen, China.
Xin DaiMedical Research Institute, Shenzhen Baoan Women's and Children's Hospital, Jinan University, Shenzhen, China.
Rui ZhangPrenatal Diagnosis Unit, Shenzhen Baoan Women's and Children's Hospital, Jinan University, Shenzhen, China.
Zhibing LiangMedical Research Institute, Shenzhen Baoan Women's and Children's Hospital, Jinan University, Shenzhen, China.
Wenzhou LiMedical Research Institute, Shenzhen Baoan Women's and Children's Hospital, Jinan University, Shenzhen, China.
Ming ZengMedical Research Institute, Shenzhen Baoan Women's and Children's Hospital, Jinan University, Shenzhen, China.
Jinfeng SuMedical Research Institute, Shenzhen Baoan Women's and Children's Hospital, Jinan University, Shenzhen, China.
Jun WangMedical Research Institute, Shenzhen Baoan Women's and Children's Hospital, Jinan University, Shenzhen, China.
Xia LiangMedical Research Institute, Shenzhen Baoan Women's and Children's Hospital, Jinan University, Shenzhen, China.
Yong WuMedical Research Institute, Shenzhen Baoan Women's and Children's Hospital, Jinan University, Shenzhen, China.
Desheng LiangHunan Key Laboratory of Medical Genetic, Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, China.
Jinan University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemophilia A (HA), a common bleeding disorder caused by a deficiency of coagulation factor VIII (FVIII), has long been considered an attractive target for gene therapy studies. However, full-length

Indexed as

CIRSPR/SaCas9gene editinggene therapyhemophilia Aintron 1 inversion

Identifiers

PMID34485274
PMCPMC8415270
OpenAlexW3195106998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.